P
ProterixBio
Developing innovative products to transform the management of chronic diseases
At a glance
- Status
- Closed
- Employees
- 16
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Testing, Biotechnology, Drug Development, Chronic Disease, Biotech and Pharma, Techbio, Hard Tech, medical testing, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Jul 2013 | $19M | — | Undisclosed | — |
| DEBTDebt | Mar 2013 | $1.1M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for ProterixBio is 240 monthly website visits, down 89.6% over the last three months. ProterixBio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ProterixBio in the Billerica ecosystem
The ProterixBio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
New York Angels- FVF2 Ventures
Series B and later4 investors entered at this stage
New Science Ventures- WVWFD Ventures
Morningside
MF Capital
Other known investors1 additional known investor
Horizon Technology Finance Corporation
Source: Dealroom Talent Intelligence.
Global footprint
See ProterixBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








